{
  "source": "PA-Notification-Jakafi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1052-13\nProgram Prior Authorization/Notification\nMedication Jakafi® (ruxolitinib)\nP&T Approval Date 1/2012, 8/2012, 7/2013, 5/2014, 5/2015, 5/2016, 5/2017, 3/2018,\n3/2019, 3/2020, 3/2021, 11/2021, 11/2022, 11/2023, 11/2024\nEffective Date 2/15/2025\nA. Background:\nJakafi® (ruxolitinib) is a kinase inhibitor indicated for treatment of patients with intermediate or\nhigh-risk myelofibrosis, including primary myelofibrosis (PMF), post-polycythemia vera\nmyelofibrosis and post-essential thrombocythemia myelofibrosis. It is also indicated in patients\nwith polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.\nIt is also indicated for the treatment of steroid-refractory acute graft-versus-host disease and\nchronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and\npediatric patients 12 years and older.\nThe National Cancer Comprehensive Network (NCCN) also recommends Jakafi for the treatment\nof polycythemia vera, essential thrombocythemia, accelerated/blast phase myeloproliferative\nneoplasm, lymphoid, myeloid/lymphoid neoplasms with eosinophilia and JAK2 rearrangement,\nmyelodysplastic syndromes, pediatric acute lymphoblastic leukemia, T-Cell Lymphomas, and\nmanagement of CAR-T-cell and immunotherapy-related toxicities.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of 19\nyears, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or under\nsome circumstances. Some states also mandate usage of other Compendium references. Where such\nmandates apply, they supersede language in the benefit document or in the notification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Jakafi will be approved based on the following criterion:\na. Patient i",
    "language in the benefit document or in the notification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Jakafi will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Myelofibrosis\n1. Initial Authorization\n1. Jakafi will be approved based on one of the following diagnoses:\n© 2024 UnitedHealthcare Services, Inc.\n1\n(1) Symptomatic lower-risk myelofibrosis\n(2) Intermediate or higher-risk myelofibrosis\n(3) Post-polycythemia vera myelofibrosis\n(4) Post-essential thrombocythemia myelofibrosis\n(5) Both of the following:\n(a) Myelofibrosis-associated anemia\n(b) Presence of symptomatic splenomegaly and/or constitutional symptoms\nAuthorization will be issued for 6 months.\n2. Reauthorization\na. Jakafi will be approved based on one of the following criteria:\n(1) Documentation that patient has evidence of symptom improvement or reduction\nin spleen volume while on Jakafi\nAuthorization will be issued for 6 months.\n-OR-\n(2) Documentation does not provide evidence of symptom improvement or\nreduction in spleen volume while on Jakafi, allow for dose titration with\ndiscontinuation of therapy\nAuthorization will be issued for 2 months.\nC. Polycythemia vera\n1. Initial Authorization\na. Jakafi will be approved based on one of the following:\n(1) Both of the following:\n(a) Diagnosis of low-risk polycythemia vera\n-AND-\n(b) History of failure, inadequate response, contraindication, or intolerance to\none of the following:\ni. Hydroxyurea\n© 2024 UnitedHealthcare Services, Inc.\n2\nii. Interferon therapy (e.g., Intron A, Pegasys)\n-OR-\n(2) Diagnosis of high-risk polycythemia vera\nAuthorization will be issued for 6 months.\n2. Reauthorization\na. Jakafi will be approved based on one of the following criteria:\n(1) Documentation that patient has evidence of symptom improvement or reduction\nin spleen volume while on Jakafi\nAuthorization will be issued for 6 months.\n-OR-\n(2) Documentation does not provi",
    "teria:\n(1) Documentation that patient has evidence of symptom improvement or reduction\nin spleen volume while on Jakafi\nAuthorization will be issued for 6 months.\n-OR-\n(2) Documentation does not provide evidence of symptom improvement or\nreduction in spleen volume while on Jakafi, allow for dose titration with\ndiscontinuation of therapy\nAuthorization will be issued for 2 months.\nD. Essential thrombocythemia\n1. Initial Authorization\na. Jakafi will be approved based on both of the following:\n(1) Diagnosis of essential thrombocythemia\n-AND-\n(2) Inadequate response or loss of response to one of the following:\n(a) Hydroxyurea\n(b) Pegasys (peginterferon alfa-2a)\n(c) Agrylin (Anagrelide)\nAuthorization will be issued for 6 months.\n2. Reauthorization\n© 2024 UnitedHealthcare Services, Inc.\n3\na. Jakafi will be approved based on one of the following criteria:\n(1) Documentation that patient has evidence of symptom improvement or reduction\nin spleen volume while on Jakafi\nAuthorization will be issued for 6 months.\n-OR-\n(2) Documentation does not provide evidence of symptom improvement or\nreduction in spleen volume while on Jakafi, allow for dose titration with\ndiscontinuation of therapy\nAuthorization will be issued for 2 months.\nE. Graft versus host disease (GVHD)\n1. Initial Authorization\na. Jakafi will be approved based on one of the following:\n(1) Both of the following:\n(a) Diagnosis of acute GVHD\n(b) Disease is steroid refractory\n-OR-\n(2) Both of the following:\n(a) Diagnosis of chronic GVHD\n(b) Failure of one or two lines of systemic therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Jakafi will be approved based on the following criterion:\n(1) Documentation of symptom improvement while on Jakafi\nAuthorization will be issued for 12 months.\nF. Myeloid/Lymphoid Neoplasms\n© 2024 UnitedHealthcare Services, Inc.\n4\n1. Initial Authorization\na. Jakafi will be approved based on both of the following:\n(1) Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms ",
    "d Neoplasms\n© 2024 UnitedHealthcare Services, Inc.\n4\n1. Initial Authorization\na. Jakafi will be approved based on both of the following:\n(1) Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with\neosinophilia\n-AND-\n(2) Patient has a JAK2 rearrangement\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Jakafi will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Jakafi therapy.\nAuthorization will be issued for 12 months.\nG. Myelodysplastic Syndromes\n1. Initial Authorization\na. Jakafi will be approved based on one of the following:\n(1) Both of the following:\n(a) Diagnosis of chronic myelomonocytic leukemia (CMML)-2\n(b) Use in combination with a hypomethylating agent (e.g., azacitidine,\ndecitabine)\n-OR-\n(2) Both of the following:\n(a) Diagnosis of myelodysplastic/myeloproliferative neoplasm (MDS/MPN)\nwith neutrophilia\n(b) Disease is positive for CSF3R or JAK2 mutation\nAuthorization will be issued for 12 months.\n2. Reauthorization\n© 2024 UnitedHealthcare Services, Inc.\n5\na. Jakafi will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Jakafi therapy.\nAuthorization will be issued for 12 months.\nH. Myeloproliferative Neoplasms\n1. Initial Authorization\na. Jakafi will be approved based on both of the following:\n(1) Diagnosis of accelerated/blast phase myeloproliferative neoplasm\n-AND-\n(2) Used for splenomegaly or other disease-related symptoms\nAuthorization will be issued for 6 months.\n2. Reauthorization\na. Jakafi will be approved based on one of the following criteria:\n(1) Documentation that patient has evidence of symptom improvement or reduction\nin spleen volume while on Jakafi\nAuthorization will be issued for 6 months.\n-OR-\n(2) Documentation does not provide evidence of symptom improvement or\nreduction in spleen volume while on Jakafi, allow for dose titration with\ndiscontinuation of therapy\nAuthorization will be issued fo",
    ") Documentation does not provide evidence of symptom improvement or\nreduction in spleen volume while on Jakafi, allow for dose titration with\ndiscontinuation of therapy\nAuthorization will be issued for 2 months.\nI. Pediatric Acute Lymphoblastic Leukemia\n1. Authorization\na. Jakafi will be approved based on both of the following:\n(1) Diagnosis of pediatric acute lymphoblastic leukemia\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n6\n(2) Used as a component of consolidation therapy\nAuthorization will be issued for 12 months.\nJ. Immunotherapy-Related Toxicities\n1. Authorization\na. Jakafi will be approved based on one of the following criteria:\n(1) Both of the following:\n(a) Diagnosis of CAR-T induced G4 cytokine release syndrome\n(b) Disease is refractory to high-dose corticosteroids and anti-IL-6 therapy\n[e.g., Actemra (tocilizumab)]\n-OR-\n(2) Both of the following:\n(a) Diagnosis of immune checkpoint inhibitor-related toxicities\n(b) Used in combination with Orencia (abatacept) for the management of\nconcomitant myositis and myocarditis\nAuthorization will be issued for 12 months.\nK. T-Cell Lymphomas\n1. Initial Authorization\na. Jakafi will be approved based on one of the following criteria:\n(1) Both of the following:\n(a) Diagnosis of one of the following:\ni. Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)\nii. Enteropathy-associated T-cell lymphoma (EATL)\niii. Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL)\niv. Angioimmunoblastic T-cell lymphoma (AITL)\nv. Nodal peripheral T-cell lymphoma with T-follicular helper phenotype\n(PTCL, TFH)\nvi. Follicular T-cell lymphoma (FTCL)\nvii. Anaplastic large cell lymphoma (ALCL)\n© 2024 UnitedHealthcare Services, Inc.\n7\n-AND-\n(b) Used as initial palliative intent therapy or second-line and subsequent\ntherapy for relapsed/refractory disease\n-OR-\n(2) Both of the following:\n(a) One of the following diagnoses:\ni. T-cell large granular lymphocytic leukemia\nii. T-cell prolymphocytic leukemia\n-AND-\n(b) Used as second-line",
    "ed/refractory disease\n-OR-\n(2) Both of the following:\n(a) One of the following diagnoses:\ni. T-cell large granular lymphocytic leukemia\nii. T-cell prolymphocytic leukemia\n-AND-\n(b) Used as second-line or subsequent therapy\n-OR-\n(3) Both of the following:\n(a) Diagnosis of hepatosplenic T-cell lymphoma\n-AND-\n(b) Used for refractory disease after two first-line therapy regimens\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Jakafi will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Jakafi therapy.\nAuthorization will be issued for 12 months.\nL. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\n© 2024 UnitedHealthcare Services, Inc.\n8\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Jakafi [package insert]. Wilmington, DE: Incyte Corporation; January 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed September\n27, 2024.\n3. Ayalew Tefferi and Animesh Pardanani. Brief Report: Serious Adverse Events During\nRuxolitinib Treatment Discontinuation in Patients With Myelofibrosis. Mayo Clin Proc.\nDecember 2011 86(12):1188-1191.\n4. Hill, J, Alousi",
    " Animesh Pardanani. Brief Report: Serious Adverse Events During\nRuxolitinib Treatment Discontinuation in Patients With Myelofibrosis. Mayo Clin Proc.\nDecember 2011 86(12):1188-1191.\n4. Hill, J, Alousi A, Kebriaei P, et al. New and emerging therapies for acute and chronic graft\nversus host disease. Ther Adv Hematol. 2018; 9(1):21-46.\n5. Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft versus host\ndisease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;\n29(10):2062-8.\n6. Zeiser R, Blazar BR. Pathophysiology of chronic graft versus host disease and therapeutic target.\nN Engl J Med. 2017; 377:2565-79.\n7. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of myeloid\nneoplasms and acute leukemia: Integrating morphological, clinical and genomic data. Blood\n2022. Epub ahead of print\nProgram Prior Authorization/Notification - Jakafi® (ruxolitinib)\nChange Control\n5/2014 Annual review with no change to coverage.\n5/2015 Added clinical criteria for polycythemia vera. Updated references.\n5/2016 Annual review. Added 6 month initial authorization time frame to\nMyeofibrosis. Updated references.\n5/2017 Annual review. Changed member to patient in coverage criteria.\nChanged word criterion to criteria in reauthorization of coverage\ncriteria.\n3/2018 Annual review. Added off label criteria for management of steroid\nrefractory GVHD based on consultant feedback and review of emerging\nevidence. Updated references.\n3/2019 Annual review. Updated criteria for polycythemia vera to align with\nNCCN recommendation. Updated references.\n3/2020 Annual review. Updated background, added general NCCN\nrecommendations for use criteria. Updated reference.\n3/2021 Annual review. Coverage criteria added for Myeloid/Lymphoid\n© 2024 UnitedHealthcare Services, Inc.\n9\nNeoplasms and Myelodysplastic Syndromes per NCCN\nrecommendations. Reference updated.\n11/2021 Updated background to include new indication for treatme",
    "/Lymphoid\n© 2024 UnitedHealthcare Services, Inc.\n9\nNeoplasms and Myelodysplastic Syndromes per NCCN\nrecommendations. Reference updated.\n11/2021 Updated background to include new indication for treatment of chronic\nGVHD. Added coverage criteria for pediatric acute lymphoblastic\nleukemia and CAR-T cell related toxicities per NCCN\nrecommendations. References updated.\n11/2022 Annual review. Updated background per prescribing information, added\nstate mandate, and updated references.\n11/2023 Annual review. Added criteria for T-cell lymphomas and essential\nthrombocythemia per NCCN recommendations. Updated criteria for\npediatric ALL. Updated criteria for GVHD per FDA label. Updated\nbackground. Updated references.\n11/2024 Annual review. Updated background per NCCN guidelines. Updated\ncriteria for myelofibrosis, polycythemia vera, graft versus host disease,\nmyeloid/lymphoid neoplasms, myelodysplastic syndromes, pediatric\nacute lymphoblastic leukemia, immunotherapy-related toxicities, and T-\ncell lymphomas. Added new section for myeloproliferative neoplasms.\nUpdated duration of approval for additional NCCN recommended\nregimens.\n© 2024 UnitedHealthcare Services, Inc.\n10"
  ]
}